Skip to content

A study to assess the safety and performance of the Relisys Post-dilatation catheters in PTCA.

A Retrospective, Open-label, Non-randomized Post-Market Clinical Follow up study to assess the safety and performance of the Relisys Post-dilatation catheters in human subjects who underwent coronary angioplasty. - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/02/062920
Enrollment
254
Registered
2024-02-20
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I708- Atherosclerosis of other arteries

Interventions

Intervention1: Post-dilatation catheter: The Post-dilatation balloon catheter is proposed to achieve better uniform stent expansion after the stent deployment. Post Dilatation Balloon catheter is used

Sponsors

Relisys Medical Devices Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.The patient must be 18 years of age or older, irrespective of gender. 2.Subjects who underwent treatment with stenotic lesions in coronary arteries or bypass graft stenosis for percutaneous coronary intervention (PCI). 3.The patient had single or multiple vessel coronary artery disease and clinical evidence of ischemic heart disease, stable or unstable angina, silent ischemia, and, or a positive functional study. 4.Underwent treatment with Relisys post-dilatation catheters during the period Jan2019–Dec 2023. 5.The subject must have denovo or restenotic lesion(s) in native coronary arteries or bypass grafts that are suitable for percutaneous coronary intervention. 6.A maximum of three lesions, including at least one target lesion, in up to two coronary arteries. 7.Target and non-target lesions must be in different coronary arteries or bypass grafts. 8.The target lesion(s) must have a diameter stenosis of greater than 70percentage by visual estimation and be amenable to percutaneous intervention.

Exclusion criteria

Exclusion criteria: 1.Pregnant Female. 2.Presence of any known life-threatening non-cardiac (major or progressive) disease that will limit the patients life expectancy. 3.Documented evidence of significant renal dysfunction dysfunction(serum creatinine less than 3.0mg per dl) or on any form of dialysis. 4.Psychiatric or behavioral disease, including known alcohol or drug abuse (continued use of alcohol, illegal drugs, or the misuse of prescription or over-the-counter drugs with negative physical or psychological consequences). 5.Subjects who have known hypersensitivity to device materials. 6.The patient has any other concurrent conditions that, in the opinion of the investigator, may compromise patient safety, privacy, and study objectives.

Design outcomes

Primary

MeasureTime frame
To assess the safety of Relisys Post-dilatation catheter in patients.Timepoint: Baseline

Secondary

MeasureTime frame
To assess the performance of Relisys Post-dilatation catheter in patients.Timepoint: Baseline.

Countries

India

Contacts

Public ContactDr Sneha Voruchu

Relisys Medical Devices Limited

Snehav@relisys.in9618080999

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026